Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Leases (2019 - 2025)

Northwest Biotherapeutics' Current Leases history spans 7 years, with the latest figure at $374000.0 for Q4 2025.

  • Quarterly results put Current Leases at $374000.0 for Q4 2025, up 14.72% from a year ago — trailing twelve months through Dec 2025 was $374000.0 (up 14.72% YoY), and the annual figure for FY2025 was $374000.0, up 14.72%.
  • Current Leases for Q4 2025 was $374000.0 at Northwest Biotherapeutics, down from $399000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $448000.0 in Q2 2025 to a low of $170000.0 in Q1 2021.
  • The 5-year median for Current Leases is $327500.0 (2022), against an average of $321650.0.
  • The sharpest move saw Current Leases tumbled 55.73% in 2021, then skyrocketed 156.0% in 2025.
  • Year by year, Current Leases stood at $317000.0 in 2021, then grew by 11.67% to $354000.0 in 2022, then dropped by 11.3% to $314000.0 in 2023, then rose by 3.82% to $326000.0 in 2024, then grew by 14.72% to $374000.0 in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $374000.0, $399000.0, and $448000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.